Kiora Licenses KIO-301 South Korea Rights to CKD for $1M Upfront
KPRX sits 50% above its 52-week low of $1.765.
Summary
Kiora Pharmaceuticals licensed South Korean rights for its KIO-301 retinal disease therapy to Chong Kun Dang Pharmaceutical for $1 million upfront plus milestones and royalties, completing its global partnership network.
Key Events · M&A and Partnerships · KPRX
-
South Korea License Deal Signed
Effective August 20, 2026, CKD receives exclusive rights to develop and commercialize KIO-301 in South Korea for ophthalmic indications.
-
$1M Upfront Payment
Within a specified period after the effective date, CKD will pay Kiora a non-refundable $1 million license fee.
-
Milestones and Royalties
Kiora is eligible for development, regulatory, and sales milestone payments, plus double-digit royalties on net sales in South Korea.
-
Global Phase 3 Coordination
Kiora anticipates that CKD, Laboratoires Théa, and Senju Pharmaceutical will coordinate a single global Phase 3 trial for KIO-301 in retinitis pigmentosa.
Analysis · KPRX · Life Sciences
Securing a licensing partner for KIO-301 in South Korea—the last major market without one—brings Kiora Pharmaceuticals $1 million upfront plus milestone payments and double-digit royalties. The deal also aligns CKD with existing partners Théa and Senju to run a single global Phase 3 trial. This validates the asset and extends Kiora's cash runway, but the upfront payment is modest relative to the company's $11.5 million market cap.
At the time of this filing, KPRX was trading at $2.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $1.76 to $2.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.